Long Noncoding RNA LINC01116 Contributes to Gefitinib Resistance in Non-small Cell Lung Cancer through Regulating
He Wang1, Binbin Lu2, Shengnan Ren1
1Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, People's Republic of China; Department of Oncology, Sir Run Run Hospital, Nanjing Medical University, Nanjing 211166, People's Republic of China.
Abstract:
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, have been established as first-line treatments for non-small cell lung cancer (NSCLC) patients and have exhibited notable clinical efficacy. However, resistance to TKIs has become one of the major obstacles in improving the therapeutic efficacy of patients with NSCLC. This study aims to investigate the role of the long non-coding RNA (lncRNA) LINC01116 in gefitinib resistance of NSCLC and explore its underlying mechanism. In this study, we found that LINC01116 is upregulated in the gefitinib-resistant NSCLC cells and tissues. Loss- and gain-of-function assays uncovered that LINC01116 downregulation sensitized gefitinib resistance, whereas the overexpression of LINC01116 conferred PC9/R cells to gefitinib resistance. Moreover, LINC01116 silencing increased IFI44 expression. Overexpression of IFI44 reversed the resistance to gefitinib in PC9/R cells, and rescue experiments confirmed that LINC01116 affects the gefitinib resistance of PC9/R cells partly dependent on regulating IFI44 expression. Moreover, downregulation of LINC01116 increased the sensitivity of PC9/R cells to gefitinib in vivo. Our study demonstrates that LINC01116 plays a critical role in gefitinib resistance of NSCLC cells by affecting IFI44 expression, providing a novel therapeutic target to overcome TKI resistance in NSCLC.
Insights
Long non-coding RNA LINC01116 promotes gefitinib resistance in non-small cell lung cancer (NSCLC) by upregulating IFI44. Downregulating LINC01116 may overcome resistance to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) in NSCLC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are first-line treatments for non-small cell lung cancer (NSCLC).
- Acquired resistance to TKIs like gefitinib poses a significant challenge to long-term patient survival and treatment efficacy.
- Understanding the molecular mechanisms underlying TKI resistance is crucial for developing effective therapeutic strategies.
Purpose of the Study:
- To investigate the role of the long non-coding RNA (lncRNA) LINC01116 in gefitinib resistance in NSCLC.
- To elucidate the underlying molecular mechanism by which LINC01116 influences gefitinib sensitivity.
- To explore LINC01116 as a potential therapeutic target for overcoming TKI resistance.
Main Methods:
- Analysis of LINC01116 expression in gefitinib-resistant NSCLC cells and tissues.
- Loss- and gain-of-function assays to assess the impact of LINC01116 on gefitinib resistance.
- Investigation of the relationship between LINC01116 and IFI44 expression.
- In vivo studies to evaluate the effect of LINC01116 downregulation on gefitinib sensitivity.
Main Results:
- LINC01116 was found to be upregulated in gefitinib-resistant NSCLC cells and tissues.
- Downregulation of LINC01116 sensitized NSCLC cells to gefitinib, while its overexpression conferred resistance.
- LINC01116 silencing increased IFI44 expression, and IFI44 overexpression reversed gefitinib resistance.
- LINC01116 affects gefitinib resistance partly through regulating IFI44 expression.
- Downregulation of LINC01116 enhanced gefitinib sensitivity in vivo.
Conclusions:
- LINC01116 plays a critical role in mediating gefitinib resistance in NSCLC.
- The mechanism involves LINC01116 regulating IFI44 expression, thereby influencing TKI sensitivity.
- LINC01116 represents a potential novel therapeutic target for overcoming TKI resistance in NSCLC patients.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
Experimental RNAi
Non-LTR Retrotransposons
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...


